Ocular Therapeutix (FRA:0OT) Piotroski F-Score: 4 (As of Jun. 27, 2026) — Near Median


FRA:0OT Ocular Therapeutix Inc FRA:0OT
51 GF Score
Price €8.45
GF Value €3.80
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Ocular Therapeutix Piotroski F-Score?

Ocular Therapeutix FRA:0OT -1.74% 51 Piotroski F-Score is 4 as of Jun. 27, 2026, which is at its 10-year median of 4.00. GuruFocus rates FRA:0OT with a GF Score™ of 51/100 and a GF Value™ of €3.80 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,342 Biotechnology companies, Ocular Therapeutix ranks better than 74.22% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ocular Therapeutix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Ocular Therapeutix's Piotroski F-Score or its related term are showing as below:

FRA:0OT' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 4

During the past 13 years, the highest Piotroski F-Score of Ocular Therapeutix was 6. The lowest was 2. And the median was 4.

Ocular Therapeutix  (FRA:0OT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ocular Therapeutix Piotroski F-Score Related Terms


Ocular Therapeutix Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Ocular Therapeutix's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix Piotroski F-Score Chart

Ocular Therapeutix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 3.00 4.00 4.00

Ocular Therapeutix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 4.00 4.00

FRA:0OT vs AUPH, NTLA, TYRA: Piotroski F-Score Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Piotroski F-Score falls into.


FRA:0OT
51GF Score
Ocular Therapeutix Inc FRA:0OT
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -58.795 + -59.144 + -55.215 + -76.649 = €-249.80 Mil.
Cash Flow from Operations was -47.891 + -43.218 + -46.329 + -57.084 = €-194.52 Mil.
Revenue was 11.669 + 12.391 + 11.315 + 9.329 = €44.70 Mil.
Gross Profit was 9.984 + 10.88 + 9.954 + 8.179 = €39.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(375.476 + 391.306 + 350.071 + 690.081 + 633.638) / 5 = €488.1144 Mil.
Total Assets at the begining of this year (Mar25) was €375.48 Mil.
Long-Term Debt & Capital Lease Obligation was €65.99 Mil.
Total Current Assets was €610.69 Mil.
Total Current Liabilities was €41.25 Mil.
Net Income was -40.669 + -32.88 + -46.211 + -59.249 = €-179.01 Mil.

Revenue was 15.274 + 13.898 + 16.313 + 9.896 = €55.38 Mil.
Gross Profit was 13.872 + 12.491 + 15.139 + 8.728 = €50.23 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(495.831 + 480.378 + 441.822 + 437.328 + 375.476) / 5 = €446.167 Mil.
Total Assets at the begining of last year (Mar24) was €495.83 Mil.
Long-Term Debt & Capital Lease Obligation was €68.51 Mil.
Total Current Assets was €358.62 Mil.
Total Current Liabilities was €35.08 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ocular Therapeutix's current Net Income (TTM) was -249.80. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ocular Therapeutix's current Cash Flow from Operations (TTM) was -194.52. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-249.803/375.476
=-0.66529685

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-179.009/495.831
=-0.36102825

Ocular Therapeutix's return on assets of this year was -0.66529685. Ocular Therapeutix's return on assets of last year was -0.36102825. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ocular Therapeutix's current Net Income (TTM) was -249.80. Ocular Therapeutix's current Cash Flow from Operations (TTM) was -194.52. ==> -194.52 > -249.80 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=65.993/488.1144
=0.13519986

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=68.513/446.167
=0.15355909

Ocular Therapeutix's gearing of this year was 0.13519986. Ocular Therapeutix's gearing of last year was 0.15355909. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=610.686/41.246
=14.80594482

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=358.617/35.082
=10.22225073

Ocular Therapeutix's current ratio of this year was 14.80594482. Ocular Therapeutix's current ratio of last year was 10.22225073. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ocular Therapeutix's number of shares in issue this year was 224.099. Ocular Therapeutix's number of shares in issue last year was 169.397. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=38.997/44.704
=0.87233805

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=50.23/55.381
=0.90698976

Ocular Therapeutix's gross margin of this year was 0.87233805. Ocular Therapeutix's gross margin of last year was 0.90698976. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=44.704/375.476
=0.11905954

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=55.381/495.831
=0.1116933

Ocular Therapeutix's asset turnover of this year was 0.11905954. Ocular Therapeutix's asset turnover of last year was 0.1116933. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ocular Therapeutix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Ocular Therapeutix (FRA:0OT) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ocular Therapeutix and its competitors. This is near median its historical median of 4.00. Over the past decade, Ocular Therapeutix's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Ocular Therapeutix ranks #346 out of 1342 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Ocular Therapeutix's Piotroski F-Score too high?
Ocular Therapeutix's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Ocular Therapeutix's value of 4 is 33.3% above this industry median. Based on the distribution chart, Ocular Therapeutix ranks #346 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Piotroski F-Score compare to AUPH and NTLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #346 out of 1342 companies for Piotroski F-Score. This puts Ocular Therapeutix in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Ocular Therapeutix's value of 4 is 33.3% above this benchmark. Historically, Ocular Therapeutix's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Ocular Therapeutix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocular Therapeutix's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ocular Therapeutix and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocular Therapeutix's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.80, compared to a current price of €8.45 — trading 122.4% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of €8.45 is trading 122.4% above its estimated GF Value™ of €3.80. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for FRA:0OT:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: €3.80 vs. price of €8.45 (122.4% above fair value)
  • GF Score™: 51/100 with 3 warning signs
  • Industry Position: 33.3% above the Biotechnology median (#346 of 1342)

No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges OCUL:USA0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score

Get the complete analysis for FRA:0OT

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.45
Price
€3.80
GF Value